NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, announced it will present at the NIBA 153rd Investment Conference on October 7, 2026, in Fort Lauderdale, Florida. The presentation comes as the company advances NV-387, a broad-spectrum antiviral drug candidate, through separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. These trials represent a critical step in validating the company's nanoviricide platform, which aims to create special purpose nanomaterials that can target a wide range of viruses.
The significance of NanoViricides' work lies in its potential to address unmet medical needs in infectious diseases. NV-387 is also being planned for clinical trials in measles, for which it has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). Additionally, the company is pursuing trials for viral acute respiratory infections. If successful, NV-387 could become a versatile treatment option for multiple viral threats, a rare achievement in antiviral development. The company's pipeline further includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS, demonstrating a broad commitment to combating viral diseases.
NanoViricides' business model is based on licensing technology from TheraCour Pharma, Inc., and its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. The company's other advanced candidate, NV-HHV-1, targets shingles. The platform technology is based on the TheraCour nanomedicine technology, which NanoViricides holds a worldwide exclusive perpetual license for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
The NIBA conference presentation provides an opportunity for NanoViricides to engage with investors and showcase its progress. The company's focus on advancing NV-387 into Phase II human clinical trials is particularly noteworthy, as it transitions from preclinical research to human testing. However, the company acknowledges the inherent risks in drug development, stating that there can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. The path to typical drug development is extremely lengthy and requires substantial capital, and success against viruses in the lab may not translate to successful clinical trials or a pharmaceutical product.
For investors and industry observers, NanoViricides' presentation at the NIBA conference is a chance to assess the company's strategic direction and the potential of its nanoviricide technology. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/vQCM4, and more information about the company is available at www.nanoviricides.com. The announcement was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
